Winner Medical(SZ:300888) Western Securities·2025-12-27 08:24Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 38.08 CNY per share, indicating a positive outlook for the stock's performance in the next 6-12 months [6]. Core Insights - The company is positioned to capitalize on structural upgrades in both the medical and consumer sectors through a dual business model of "medical + consumer" [1][6]. - The medical industry is transitioning from basic consumables to high-value products such as advanced dressings and customized surgical packs, driven by aging populations and rising medical standards [1]. - The consumer side is focusing on high-quality, safe, and environmentally friendly products, reflecting a trend towards health and quality of life [1]. Financial Performance - For the first three quarters of 2025, the company reported revenues of 7.897 billion CNY, a 30.10% increase year-over-year, and a net profit of 732 million CNY, up 32.36% [2]. - The consumer segment generated 4.01 billion CNY in revenue, with significant growth in key product categories: 63.9% for cotton soft towels, 15.7% for high-end sanitary napkins, and 17.3% for comfortable cotton clothing [2]. - The medical segment's revenue reached 3.83 billion CNY, marking a 44.4% increase, driven by the acquisition of GRI, which boosted surgical consumables by 185.3% [2]. Growth Projections - The company is expected to continue its global expansion, focusing on high-value medical products and enhancing synergies from the GRI acquisition [3]. - The strategic plan for the next three years includes specific growth targets and an employee stock incentive program to drive internal motivation [3]. - Earnings per share (EPS) projections for 2025-2027 are 1.78 CNY, 2.13 CNY, and 2.44 CNY, with corresponding price-to-earnings (P/E) ratios of 21.3, 17.9, and 15.6 [3][4].